Articles

Durezol 0.05% (difluprednate ophthalmic emulsion; Sirion Therapeutics Inc), a topical corticosteroid to treat postoperative ocular inflammation and pain, is now commercially available, following FDA approval in June 2008.

Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.

LASEK produces better safety and efficacy outcomes than Epi-LASIK, according to a study published in the September edition of the American Journal of Ophthalmology.

Consumption of caffeine prevents against the formation of cataracts due to ultraviolet (UV) light radiation, according to study results published in the October edition of the Journal of Ocular Pharmacology and Therapeutics.

Consuming dark-coloured fruits and vegetables increases the levels of macular pigment (MP) and is associated with improved vision in age-related macular degeneration (AMD) sufferers, according to study results published in the New Straits Times Online on September 22.

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma.

Perioperative use of mitomycin-C (MMC) improves the long-term outcomes of trabeculectomy as a treatment for primary open-angle glaucoma (POAG), according to a study published online ahead of print by the British Journal of Ophthalmology.

VEGF Trap-Eye, Regeneron's treatment for wet age-related macular degeneration (AMD), has demonstrated improved visual acuity (VA) and reduced biological markers of neovascular disease at one year of follow-up, according to final Phase II results presented at this year's Scientific Meeting of the Retina Society, held September 26–28 in Scottsdale, Arizona, US.

NeoVista's epiretinal brachytherapy for wet age-related macular degeneration (AMD) increases the visual acuity of eyes treated with bevacizumab (Avastin) at 18 months, according to Phase II study results announced on September 29th at this year's Scientific Meeting of the Retina Society in Scotsdale, Arizona, US.

Optical is just as good as digital pachymetry say Mohammed Hassan & Ali Yagan

Red wavelength should not be forgotten, Professor Michael Stur advises.

News In Focus, October 2008

An article authored by Josef Reiter, MD, titled "My way to Epi-LASIK", which appeared in the July/August issue of Ophthalmology Times Europe, contained an error on page 20.

Outcomes are equivalent to or better than femtosecond procedures, says Dr Richard Duffey

Eighteen-month results confirm safety & efficacy says Dr Norbert Koerber.

Dr James Tsai outlines key points to ensure a good outcome.

European Ophthalmology, the social networking group for European ophthalmologists created and moderated by Ophthalmology Times Europe, has recently launched its new discussion forum.

New techniques are better than traditional cross-linking, according to Dr Massimo Lombardi

News from the ophthalmology industry, October 2008

In this month's issue, we take a look at the impact of eye disease from a patient's point of view.

Bausch & Lomb and Schwind are following the latest industry trend by forming strategic alliances with femtosecond laser manufacturers 20/10 Perfect Vision and Ziemer Ophthalmic Systems, respectively.

John Morrow discusses the potential applications of stem cell therapy in retina disease treatment

You can leave the epithelium intact, say Dr Roberto Pinelli and Dr Tarek El Beltagi

Daily treatment with pirenzepine gel can slow the rate of progressive myopia in children, according to a study published in the August issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus.

Don't deny patients access to care known to be effective say Ken Bradley & Timothy Gels

Dr George Beiko advises on how to prepare patients for the gradual postoperative changes

David Bailey, president of international operations at Staar Surgical, makers of the Visian ICL & TICL, says ICL technology allows surgeons to differentiate themselves in the slowing LASIK marketplace. Mr Bailey was speaking at a media briefing during this year's congress of the ESCRS in Berlin, Germany.

A camera the size and shape of a human eye could have a diverse range of applications, including being used as a retinal implant and in brain monitoring and cardiac stimulation, according to research published in Nature.

Product watch, October 2008

Vaccines may have a role to play against corneal and external ocular disease, because of their success in preventing systemic diseases, according to a presentation given during Cornea Day at the annual meeting of the American Society of Cataract and Refractive Surgery earlier this year.